Non-parametric analysis was used (Wilcoxon and Mann-Whitney tests).
Results: After 5 months of IPC foot+calf Median ICD, ACD, resting and post exercise ABPI in group 1 increased by 197, 212, 17, and 64 percent (all P<0.001) respectively; changes in group 2 were all non-significant (P>0.1). On intergroup comparison at 5 months, patients in group 1 were better than those in group 2 in terms of ICD, ACD, resting and postexercise ABPI (all P < 0.01). Q changes within this period were not significant in either group; neither were intergroup Q differences (P > 0.1). Associated changes in the quality of life within group 1 at the of month 5 were significant; non-significant changes were noted in group 2. At 5 months patients in group 1 enjoyed a better quality of life than those in group 2 (P < 0.01). IPC foot+calf use did not result in any complications. The daily IPC foot+calf compliance (2.5 h per day) was greater than 82 percent in the first month and greater than 85 percent in months 2-5. Once year after the end of IPC foot+calf application, patients in group 1 maintained the improved ABPI and walking benefit.
Conclusion:
IPC foot+calf emerged as an effective, high-compliance, uncomplicated method for improving the walking ability and pressure indices in patients with stable claudication, with a confirmed durable outcome. These changes are associated with a significant improvement in all aspects of quality of life evaluated by the SF-36. Despite a limited benefit noted in some individuals, unsupervised exercise had a non-significant impact overall.
